Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
This describes an investigational drug approach (PALI-2108) aimed at intestinal fibrosis, a key issue in fibrostenotic Crohn’s disease for which there are no approved antifibrotic therapies. Patients and clinicians may want to follow progress toward later-stage trials.
Patients with Crohn’s disease, especially those with fibrostenotic disease or strictures; clinicians treating IBD; researchers focused on fibrosis and drug development.
What To Know
Palisade Bio announced a company presentation at a New York Academy of Sciences symposium about PALI-2108, a locally bioactivated oral PDE4 inhibitor prodrug being developed for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis.
The release summarizes the presentation focus (fibrosis biology, rationale for PDE4 inhibition, and preclinical findings) and notes Phase 1 studies have been completed with plans to advance toward Phase 2 in UC and Crohn’s disease.
What To Know PALI-2108 is an investigational, locally bioactivated PDE4 inhibitor prodrug intended to concentrate activity in the ileum and colon. The company will present its scientific rationale for using PDE4 inhibition to target inflammatory and fibrotic pathways in FSCD at an academic symposium.
The communication is a paid press release from the company and summarizes preclinical findings and prior early-phase trial activity; it does not provide detailed trial data or new clinical results. It emphasizes the unmet need in fibrostenotic Crohn’s disease and the company’s development plans.
If you want details about safety, efficacy, or whether this therapy will be available to patients, look for peer-reviewed results from their Phase 2 studies or independent academic presentations rather than this press release.
This is a company press release about a planned symposium presentation and summarizes preclinical rationale and prior early-phase studies; it does not report new clinical efficacy or safety results. Early-phase positive signals do not guarantee success in later trials.
